Advanced Biomed agrees to acquire Acellent Technologies for 270K shares valued at $1.08M

Advanced Biomed Inc.

Acquiring 100% of Acellent Technologies (Hong Kong), an AI-powered financial verification company.
Purchase price: 270,000 shares of ADVB common stock valued at $4.00/share, total $1,080,000.
Closing subject to completion of due diligence and receipt of regulatory approvals.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Advanced Biomed Inc. entered into Share Purchase Agreement with Acellent Technologies (Hong Kong) Co. Limited and the sole shareholder of the Target valued at 270,000 shares of the Company’s common stock, par value $0.001 per share, with an estimated value of (effective 2026-04-02).

Action: entry
Agreement: asset purchase
Counterparty: Acellent Technologies (Hong Kong) Co. Limited and the sole shareholder of the Target
Value: 270,000 shares of the Company’s common stock, par value $0.001 per share, with an estimated value of
Effective: 2026-04-02

Exact text from the filing

On April 2, 2026, Advanced Biomed Inc. (the “Company”) entered into a Share Purchase Agreement (the “Agreement”) with Acellent Technologies (Hong Kong) Co. Limited (the “Target”) and the sole shareholder of the Target (the “Seller”), pursuant to which the Company agreed to purchase from Seller 100% of the equity interest in the Target (the “Acquisition”).

View on SEC.gov

281 material agreements filed in the last 30 days. Browse all material agreements →

Advanced Biomed Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-040030

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.